Advertisement
Advertisement

SLXN

SLXN logo

Silexion Therapeutics Corp Ordinary Shares

2.70
USD
Sponsored
-0.01
-0.37%
Jun 24, 15:55 UTC -4
Closed
exchange

After-Market

2.70

0.00
-0.04%

Silexion Therapeutics Corp Ordinary Shares Profile

About

Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. Silexion Therapeutics Ltd., formerly known as Biomotion Sciences, is based in NEW YORK.

Info & Links

CEO

Ilan Hadar

Headquarters

12 ABBA HILLEL ROAD
RAMAT GAN, L3 5250606, ISRAEL

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.silexion.com

Auditor

Kesselman & Kesselman

Share holders

32

Employees

14

Silexion Therapeutics Corp Ordinary Shares Statistics

Valuation Measures

Market Capitalization2

2.87M

Enterprise Value

429.35K

Enterprise Value/EBITDA(ttm)

-0.03

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.33

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-387.82%

Return on Invested Capital(ttm)

-250.80%

Return on Assets(ttm)

-144.68%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-12.72M

Net Income Available to Common(ttm)

-12.91M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

0.06

52-Week Change

-97.79%

S&P 500 52-Week Change

20.78%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

419.00K

Dividend Yield

0.00%

Float4

2.48M

% Held by Insiders

20.60%

% Held by Institutions

10.95%

Balance Sheet

Total Cash(mrq)

2.44M

Total Cash Per Share(mrq)

5.82

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

60.24%

Current Ratio(mrq)

2.41%

Quick Ratio(mrq)

2.41%

Book Value Per Share(mrq)

0.83

Cash Flow

Operating Cash Flow Per Share(ytd)

-8.14

Free Cash Flow(ytd)

-10.83M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement